Using DNA nanostructures to improve drug delivery and biosensing
Programmable DNA Nanostructures as Biomedical and Structural Scaffolds
This study is working on a new way to use tiny DNA structures to deliver medicines more effectively to treat conditions like myotonic dystrophy type 1, helping to improve how well these treatments work in the body.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | State University of New York at Albany NIH-funded |
| Lab location | 1 site (Albany, United States) |
| Project ID | NIH-10895409 on NIH RePORTER |
What this research studies
This research focuses on developing programmable DNA nanostructures that can precisely position therapeutic molecules, such as drugs and antibodies, for various biomedical applications. The project aims to create a multifunctional drug delivery system specifically targeting multisystemic diseases, using myotonic dystrophy type 1 as a model. Additionally, it explores the use of 3D DNA crystals as scaffolds for advanced imaging techniques to better understand molecular structures. By validating the efficiency of these DNA-based systems in cell cultures and preclinical models, the research seeks to enhance drug bioavailability and targeting.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with myotonic dystrophy type 1 or other multisystemic diseases that could benefit from advanced drug delivery methods.
Not a fit: Patients with conditions unrelated to drug delivery or those not affected by multisystemic diseases may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and targeted drug delivery systems, improving treatment outcomes for patients with complex diseases.
How similar studies have performed: While DNA nanotechnology is a rapidly evolving field, this specific approach to drug delivery and biosensing is relatively novel and has not been extensively tested in clinical settings.
Where this research is happening
Albany, United States
- State University of New York at Albany — Albany, United States (Active)
Researchers
- Principal investigator: Chandrasekaran, Arun Richard — State University of New York at Albany
- Study coordinator: Chandrasekaran, Arun Richard
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.